Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 2.64M | 2.76M | 3.53M | -782.00K | 5.70M |
Gross Profit | 2.43M | 2.57M | 3.21M | -981.00K | 5.56M |
EBITDA | -64.30M | -51.22M | -32.44M | -21.62M | -18.61M |
Net Income | -61.02M | -49.12M | -33.61M | -23.01M | -21.36M |
Balance Sheet | |||||
Total Assets | 76.17M | 95.21M | 95.57M | 13.53M | 38.09M |
Cash, Cash Equivalents and Short-Term Investments | 66.81M | 87.59M | 83.78M | 10.90M | 35.79M |
Total Debt | 16.53M | 1.69M | 11.87M | 5.67M | 9.46M |
Total Liabilities | 43.22M | 27.17M | 43.04M | 84.76M | 86.63M |
Stockholders Equity | 32.96M | 68.04M | 52.53M | -71.23M | -48.54M |
Cash Flow | |||||
Free Cash Flow | -50.85M | -46.20M | -29.88M | -19.70M | -26.72M |
Operating Cash Flow | -50.56M | -46.13M | -29.29M | -19.43M | -26.18M |
Investing Cash Flow | 13.09M | 10.69M | -64.12M | 13.02M | 26.97M |
Financing Cash Flow | 29.17M | 46.22M | 103.26M | -3.99M | 10.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.39B | 0.36 | -62.86% | 2.37% | 15.48% | -2.68% | |
50 Neutral | $390.31M | ― | -189.46% | ― | -3.24% | 31.00% | |
49 Neutral | $309.59M | ― | -50.77% | ― | ― | -54.29% | |
48 Neutral | $126.87M | ― | -179.12% | ― | 30.23% | -21.32% | |
39 Underperform | $165.20M | ― | -77.83% | ― | ― | -2.29% | |
37 Underperform | $309.06M | ― | -65.19% | ― | ― | -47.28% | |
35 Underperform | $426.86M | ― | -108.92% | ― | ― | 32.58% |
On August 1, 2025, Orchestra BioMed Holdings announced the pricing of its underwritten public offering, which included 9,413,637 shares of common stock and pre-funded warrants, raising approximately $40 million. The proceeds will support the company’s atrioventricular interval modulation therapy program, the BACKBEAT study, the Virtue SAB program, and other research and development initiatives. The offering closed on August 4, 2025, and was part of a broader strategy to advance its cardiovascular care technologies.
The most recent analyst rating on (OBIO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Orchestra BioMed Holdings stock, see the OBIO Stock Forecast page.
On July 31, 2025, Orchestra BioMed Holdings announced securing $70 million in strategic capital from Ligand Pharmaceuticals and Medtronic to advance its late-stage cardiology programs. This investment includes Ligand’s $40 million commitment and Medtronic’s $30 million, reflecting confidence in Orchestra BioMed’s clinical progress and potential. The collaboration with Medtronic has been expanded to potentially integrate AVIM therapy into leadless pacemaker technology, aiming to transform care for patients with uncontrolled hypertension. This financial backing and strategic alignment are expected to support Orchestra BioMed in achieving key milestones in its high-impact clinical programs, addressing significant unmet medical needs in global markets.
The most recent analyst rating on (OBIO) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Orchestra BioMed Holdings stock, see the OBIO Stock Forecast page.
On June 24, 2025, Orchestra BioMed Holdings, Inc. held its Annual Meeting of Stockholders, where stockholders voted on two key proposals. The election of three Class II directors, Chris Cleary, Pamela Connealy, and David Pacitti, was confirmed, and the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
The most recent analyst rating on (OBIO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Orchestra BioMed Holdings stock, see the OBIO Stock Forecast page.